KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Leggett & Platt (LEG) Change in Accured Expenses (2016 - 2025)

Leggett & Platt (LEG) has disclosed Change in Accured Expenses for 17 consecutive years, with -$7.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses fell 171.43% year-over-year to -$7.6 million, compared with a TTM value of -$4.3 million through Dec 2025, up 86.93%, and an annual FY2025 reading of -$4.3 million, up 86.93% over the prior year.
  • Change in Accured Expenses was -$7.6 million for Q4 2025 at Leggett & Platt, down from $33.9 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $33.9 million in Q3 2025 and bottomed at -$32.5 million in Q4 2023.
  • Average Change in Accured Expenses over 5 years is -$6.5 million, with a median of -$6.4 million recorded in 2022.
  • The sharpest move saw Change in Accured Expenses tumbled 750.0% in 2022, then surged 290.38% in 2023.
  • Year by year, Change in Accured Expenses stood at -$4.3 million in 2021, then crashed by 367.44% to -$20.1 million in 2022, then plummeted by 61.69% to -$32.5 million in 2023, then soared by 91.38% to -$2.8 million in 2024, then crashed by 171.43% to -$7.6 million in 2025.
  • Business Quant data shows Change in Accured Expenses for LEG at -$7.6 million in Q4 2025, $33.9 million in Q3 2025, and -$5.2 million in Q2 2025.